ERBB2 and breast carcinoma: The overall consensus amongst participants was that the role of pCR in chemotherapy decision-making is well-entrenched in HER2-positive breast cancer, modestly useful in the triple-negative setting, and “so rarely achieved that it doesn’t affect what you do for the vast majority of patients” in the ER-positive setting (Table 2).